Investing in Life Science Innovation
RiverVest closes on its oversubscribed $184.4 million RiverVest Fund IV
The fund marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Dec. 31 to $832 million.
Also in this issue:
RiverVest recognized as Investor of the Year
Sivan Weitzman joins RiverVest as its first CFO
Portfolio company news from Allakos, Arch Oncology, Cardialen, Mirum Pharmaceuticals, Spruce Bioscience and WUGEN
RiverVest Venture Partners announced today that Ronald T. Borchardt, Ph.D. and Jared Rutter, Ph.D. have joined the life science venture capital firm’s Scientific Advisory Board.
Also in this issue:
Portfolio company news from Allakos, Amplyx, Avalyn Pharma, Spruce Biosciences, Tryton Medical and VentureMed Group
RiverVest Closes on $15 Million Biopharma Seed Fund
RiverVest’s new Archer Seed Fund will invest pre-seed and seed funding in about 10 early-stage biopharma companies. Investment opportunities will be sourced primarily from leading medical research institutions in St. Louis, the Midwest, and elsewhere in the U.S.
Also in this issue:
Karen Gheesling Mullis joins RiverVest
RiverVest Annual Meeting is April 11, 2017
Portfolio company news from Allakos, Amplyx, Tioma and Tryton
“Th
is is a fantastic example of what St. Louis-based innovation, talent and resources can do to build biopharma companies that will make a difference,” said John McKearn, RiverVest managing director and Tioma board chairman.
Also in this issue:
RiverVest’s Fund II Continues to perform in Top 5% of VC funds
RiverVest Adds Analyst in St. Louis Office
Portfolio company news from Allakos, Amplyx, Otonomy and Securus
“Nancy has a great history identifying successful investments,” said RiverVest Managing Director and co-founder Jay Schmelter. “She brings both scientific and transactional expertise and is well respected for her opinions and views on the venture industry. We’re excited to have her join the team.”
Also in this issue:
RiverVest’s Fund III has Strong Start
RiverVest’s Fund II Performs in Top 5% of VC Funds
Portfolio company news from Allakos, Amplyx, Otonomy and Vasculox
What if you could create a biotech startup focused on treating rare diseases, with clinical-stage drug candidates already in hand, and high odds of success in clinical trials?
RiverVest Venture Partners’ hands-on investment strategy netted big returns for its Fund I and II investors in 2011: the sale of two biopharmaceutical and two medical device companies, worth more than $1 billion.
Otonomy, Inc. is on the verge of revolutionizing the way doctors treat hearing and balance disorders. “The ear is one of the last great frontiers of pharmaceutical science,” says Jay Lichter, Ph.D., co-founder of Otonomy.
Mpex Pharmaceiticals will soon complete patient enrollment for two Phase II clinical trials for its proprietary MP-376 inhaled antibiotic formulation aided by a $27.5 million capital infusion led by Investor Growth Capital.
RiverVest Venture Partners, in an oversubscribed syndication with Alta Partners and ProQuest Investments, closed in November on a $15.5 million Series A financing of Excaliard Pharmaceuticals.
RiverVest Venture Partners recently led a $19 million Series B financing round for IDev Technologies, Inc., an emerging leader in the treatment of peripheral artery disease (PAD) through the development and marketing of the SUPERA stent system. Joining RiverVest in the Series B round was Bay City Capital, a San Francisco based venture capital firm.
